Comparative Pharmacology
Head-to-head clinical analysis: APHTHASOL versus HC 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APHTHASOL versus HC 4.
APHTHASOL vs HC #4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aphthasol (amlexanox) is an anti-inflammatory agent that inhibits the formation and release of inflammatory mediators such as histamine and leukotrienes from mast cells, neutrophils, and other inflammatory cells. It also inhibits the activation of eosinophils and neutrophils, and reduces cytokine production, thereby suppressing the immune response involved in aphthous ulcer formation.
HC #4 is a complex homeopathic preparation with no well-defined molecular mechanism; it is believed to act via hormesis or placebo effects.
Adults: 5 mg orally three times daily for 5 days.
Hydrocortisone 100-300 mg IV bolus, followed by 100-200 mg IV every 6 hours for 24-48 hours; then taper as clinically indicated.
None Documented
None Documented
Terminal elimination half-life is 1.5 to 2.5 hours. This short half-life supports multiple daily dosing for local therapeutic effect with minimal systemic accumulation.
Terminal elimination half-life: 12 hours (range 10–14 hours). Extends to 24 hours in severe renal impairment (CrCl <30 mL/min); dose adjustment recommended.
Renal excretion of unchanged drug and metabolites accounts for approximately 50-60% of the administered dose, with the remainder eliminated via biliary/fecal routes as metabolites and unchanged drug. Biliary excretion constitutes about 20-30%.
Renal excretion of unchanged drug: 95%; fecal/biliary: <5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid